Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001043657 | SCV001207413 | uncertain significance | Hereditary breast ovarian cancer syndrome | 2023-01-31 | criteria provided, single submitter | clinical testing | This sequence change replaces histidine, which is basic and polar, with tyrosine, which is neutral and polar, at codon 1856 of the BRCA2 protein (p.His1856Tyr). This variant is present in population databases (rs755791142, gnomAD 0.02%). This missense change has been observed in individual(s) with clinical features of BRCA2-related conditions (PMID: 21520333). ClinVar contains an entry for this variant (Variation ID: 841439). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt BRCA2 protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Genetic Services Laboratory, |
RCV001819757 | SCV002067801 | uncertain significance | not specified | 2019-11-18 | criteria provided, single submitter | clinical testing | |
University of Washington Department of Laboratory Medicine, |
RCV003158324 | SCV003848917 | likely benign | Hereditary cancer-predisposing syndrome | 2023-03-23 | criteria provided, single submitter | curation | Missense variant in a coldspot region where missense variants are very unlikely to be pathogenic (PMID:31911673). |
Ambry Genetics | RCV003158324 | SCV004005526 | uncertain significance | Hereditary cancer-predisposing syndrome | 2023-06-04 | criteria provided, single submitter | clinical testing | The p.H1856Y variant (also known as c.5566C>T), located in coding exon 10 of the BRCA2 gene, results from a C to T substitution at nucleotide position 5566. The histidine at codon 1856 is replaced by tyrosine, an amino acid with similar properties. This amino acid position is not well conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
All of Us Research Program, |
RCV004004763 | SCV004846597 | uncertain significance | Breast-ovarian cancer, familial, susceptibility to, 2 | 2023-11-09 | criteria provided, single submitter | clinical testing |